Category: receptor_pharmacology
Explains the brief electric-shock-like sensations in the head — often triggered by lateral eye movement — that hit users when they miss a dose or taper an SSRI or SNRI. 'Brain zaps' (also: brain shivers, electric jolts) sit alongside dizziness, nausea, flu-like malaise, sleep disturbance, and emotional lability under the umbrella of antidepressant discontinuation syndrome (Black 2000 first proposed formal diagnostic criteria; Haddad 1997 was the early canonical description). Incidence is half-life-driven: short-half-life agents like paroxetine and venlafaxine are the worst (Davies 2019 systematic review put discontinuation symptom incidence at ~56% pooled across studies), while fluoxetine — t½ of 1-4 days plus an active metabolite norfluoxetine of 7-15 days — produces it rarely because the drug self-tapers. Mechanism is incompletely understood and likely multifactorial: sudden 5-HT transporter availability rebound, a hypothesized cholinergic-serotonergic balance shift, GABAergic system perturbation, and oculomotor-saccade-coupled sensory disturbance that explains the eye-movement trigger. Henssler 2024 meta-analysis is the most rigorous recent quantification — incidence and severity is real but had been overstated in some earlier work without placebo controls. Symptoms typically resolve within 1-6 weeks; bridging with a fluoxetine swap or extreme-slow taper (months, sometimes hyperbolic dose reduction) is the standard mitigation. Distinct from SSRI rebound (relapse of underlying depression) and from serotonin syndrome (acute toxic excess). Common misattribution: users sometimes interpret zaps as relapse or new disorder rather than a discontinuation effect.